Prediction of progression of non-muscle invasive bladder cancer by WHO 1973 and 2004 grading and by FGFR3 mutation status: A prospective study

被引：0
|
作者：
Zwarthoff, Ellen
Burger, Maximilian
Van der Aa, Madelon
Van Oers, Johanna
Brinkmann, Anke
Van der Kwast, Theodorus
Steyerberg, Ewout
Stoehr, Robert
Kirkels, Wim
Denzinger, Stefan
Wild, Peter
Wieland, Wolf
Hofstaedter, Ferdinand
Hartmann, Arndt
机构：
[1] Erasmus MC, Rotterdam, Netherlands
[2] Univ Regensburg, Regensburg, Germany
[3] Toronto Gen Hosp, Toronto, ON, Canada
[4] Univ Hosp Zurich, Zurich, Switzerland
[5] Univ Erlangen Nurnberg, Erlangen, Germany
来源：
CANCER RESEARCH | 2008年 / 68卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4951
引用
收藏
页数：2
相关论文
共 50 条
  • [41] A urinary assay for mutation and methylation biomarkers in the diagnosis and recurrence prediction of non-muscle invasive bladder cancer patients
    Huang, Hai
    Liu, Ao
    Liang, Yiming
    Xin, Yaqun
    Liu, Jiacheng
    Hao, Yining
    Huang, Da
    Chen, Lu
    Li, Wei
    Jiang, Guangliang
    Huang, Yuhua
    Xu, Yaoting
    Zhang, Jie
    Ma, Tonghui
    Xu, Danfeng
    Gao, Yi
    BMC MEDICINE, 2023, 21 (01)
  • [42] Prospective study of FGFR3 mutations as a prognostic factor in nonmuscle invasive urothelial bladder carcinomas
    Hernandez, Silvia
    Lopez-Knowles, Elena
    Lloreta, Josep
    Kogevinas, Manolis
    Amoros, Alex
    Tardon, Adonina
    Carrato, Alfredo
    Serra, Consol
    Malats, Nuria
    Real, Francisco X.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (22) : 3664 - 3671
  • [43] Precise grading of non-muscle invasive bladder cancer with multi-scale pyramidal CNN
    Shalata, Aya T.
    Alksas, Ahmed
    Shehata, Mohamed
    Khater, Sherry
    Ezzat, Osama
    Ali, Khadiga M.
    Gondim, Dibson
    Mahmoud, Ali
    El-Gendy, Eman M.
    Mohamed, Mohamed A.
    Alghamdi, Norah S.
    Ghazal, Mohammed
    El-Baz, Ayman
    SCIENTIFIC REPORTS, 2024, 14 (01):
  • [44] The 1973 WHO Classification Is More Suitable than the 2004 WHO Classification for Predicting Prognosis in Non-Muscle- Invasive Bladder Cancer
    Chen, Zhongqing
    Ding, Weihong
    Xu, Ke
    Tan, Jun
    Sun, Chuanyu
    Gou, Yuancheng
    Tong, Shijun
    Xia, Guowei
    Fang, Zujun
    Ding, Qiang
    PLOS ONE, 2012, 7 (10):
  • [45] Positive association of collagen type I with non-muscle invasive bladder cancer progression
    Brooks, Michael
    Mo, Qianxing
    Krasnow, Ross
    Ho, Philip Levy
    Lee, Yu-Cheng
    Xiao, Jing
    Kurtova, Antonina
    Lerner, Seth
    Godoy, Gui
    Jian, Weiguo
    Castro, Patricia
    Chen, Fengju
    Rowley, David
    Ittmann, Michael
    Chan, Keith Syson
    ONCOTARGET, 2016, 7 (50) : 82609 - 82619
  • [46] COMPARISON OF WHO 1973 TO WHO 2004 GRADING SYSTEM IN BLADDER CANCER RELATED TO ASSOCIATION TO CIS, RECURRENCE AND PROGRESSION IN TA TUMOURS
    Sos, L.
    Palou, J.
    Huguet, J.
    Urdaneta, G.
    Rosales, A.
    Algaba, F.
    Oliver, A.
    Esquena, S.
    Villavicencio, H.
    EUROPEAN UROLOGY SUPPLEMENTS, 2009, 8 (04) : 289 - 289
  • [47] Maspin protein expression correlates with tumor progression in non-muscle invasive bladder cancer
    Kramer, Mario W.
    Waalkes, Sandra
    Hennenlotter, Jorg
    Serth, Jurgen
    Stenzl, Arnulf
    Kuczyk, Markus A.
    Merseburger, Axel S.
    ONCOLOGY LETTERS, 2010, 1 (04) : 621 - 626
  • [48] FOXM1 predicts disease progression in non-muscle invasive bladder cancer
    Sebastien Rinaldetti
    Ralph Wirtz
    Thomas Stefan Worst
    Arndt Hartmann
    Johannes Breyer
    Lars Dyrskjot
    Philipp Erben
    Journal of Cancer Research and Clinical Oncology, 2018, 144 : 1701 - 1709
  • [49] Chromosomal imbalance in the progression of high-risk non-muscle invasive bladder cancer
    Zieger, Karsten
    Wiuf, Carsten
    Jensen, Klaus Moller-Ernst
    Orntoft, Torben Falck
    Dyrskjot, Lars
    BMC CANCER, 2009, 9
  • [50] Chromosomal imbalance in the progression of high-risk non-muscle invasive bladder cancer
    Karsten Zieger
    Carsten Wiuf
    Klaus Møller-Ernst Jensen
    Torben Falck Ørntoft
    Lars Dyrskjøt
    BMC Cancer, 9 (1)
12345